Pharmaceuticals

Haleon

Salesforce

Conference Minutes

INFA

OpenAI

DXYZ

GOOG

GOOGL

GGLS

GGLL

ARR-C

The following are the minutes of the FY26Q3 earnings call for $Salesforce(CRM.US) compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article &#34;Salesforce: Is the AI Agent 'Delayed', and Has the SaaS Leader Become a Value Stock?&#34; 1. Review of Core Financial Information Guidance: The company is still expected to reaccelerate revenue growth within the next 12 to 18 months. Net new AOV growth: Net new AOV growth in the second half of FY26 is expected to exceed AOV growth in the second half...

Informatica

Destiny Tech100

Alphabet - C

Alphabet

IRSA Inversiones

NOVARTIS AG

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Armour Residential Reit

Gartner

Hasbro

ING Groep

ARMOUR RESIDENTIAL REIT INC 7.00% CUM RED PFD STK SER C

Salesforce (Minutes): The foundation of technology and sales has been laid, looking forward to the harvest period

Jefferies Analyst Maintains Buy Rating on Haleon plc with a Price Target of £450.00

Haleon Invests $86.6 Million in a New Oral Health Factory in Shanghai

Kepler Capital analyst reiterates buy rating on Haleon PLC

Haleon released FY2025 Q4 earnings on February 25 (EST), actual revenue USD 3.736 B (forecast USD 3.711 B), actual EPS USD 0.1292

Haleon released FY2025 9 Months earnings on February 25, 2026 (EST), with actual revenue of USD 11.03 B and actual EPS of USD 0.3662

Haleon released FY2025 Annual Earnings on February 25 (EST), Actual Revenue USD 14.78 B (Forecast USD 14.9 B), Actual EPS USD 0.4956 (Forecast USD 0.499)

Haleon released FY2025 Q3 earnings on February 25 (EST), actual revenue USD 3.728 B (forecast USD 3.713 B), actual EPS USD 0.129

Haleon to Release FY2025 Earnings on February 24, 2026 (EST), Forecast Revenue USD 15.11 B, EPS USD 0.499

Berenberg Bank Maintains Buy Rating on Haleon PLC

Hayes Maintains Buy Rating on Haleon PLC

Nicolai Analyzes and Recommends Consumer Staples Industry Stocks

Drive Wealth Management LLC Increases Holdings in Haleon PLC

Haleon collaborates with Sharjah University to enhance UAE healthcare education

David Hayes Upgrades Haleon PLC to Buy with Raised Earnings Forecast

Haleon Chooses Salesforce Life Sciences Cloud to Enhance Customer Engagement

RBC Reiterates Haleon's 'Sector Perform' Rating

Haleon released FY2025 Q1 earnings on July 31 (EST), actual revenue USD 0 (forecast USD 3.706 B), actual EPS USD 0

Haleon released FY2025 Semi-Annual earnings on July 31 After-Market (EST), actual revenue USD 7.303 B (forecast USD 7.527 B), actual EPS USD 0.2372

Haleon released FY2025 Q2 earnings on July 31 After-Market EST, actual revenue USD 3.756 B (forecast USD 3.602 B), actual EPS USD 0.1219

Haleon PLC Gets Buy Recommendations from Several Rating Agencies

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

Haleon PLC announced that Senior Independent Director Alan Stewart purchased 498 shares at £3.3105 each through a dividend reinvestment on May 14, 2026. This transaction enhances insider alignment with shareholders and increases transparency regarding board shareholdings. The latest analyst rating for Haleon stock (GB:HLN) is a Buy with a £4.15 price target, while TipRanks’ AI Analyst rates it as Neutral due to solid financial performance but weaker near-term momentum.

Tip Ranks

Haleon discloses dividend-driven share purchase by senior independent director

Haleon has launched a series of soccer initiatives, including a partnership with UEFA Medical to enhance pain management in sports. The London-based consumer health company, which spun out of GSK in 2022, made its painkiller Voltaren an official UEFA Champions League product and initiated a marketing campaign with the U.S. Soccer Federation. The multiyear partnership aims to improve scientific understanding of pain management through educational tools. Haleon and UEFA Medical have also co-authored an analysis on non-steroidal anti-inflammatory drugs for sports injuries, marking a significant collaboration in the field.

Fiercepharma

GlaxoSmithKline plc

Bristol Myers Squibb

Sanofi

Amgen

GSK plc Sponsored ADR

Bristol-Myers Squibb Company

Haleon tackles sports injuries with latest soccer play

Bernstein analyst maintained a Hold rating on Haleon PLC yesterday. The company’s shares closed yesterday at p335.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Bernstein, Haleon PLC also received a Hold from RBC Capital’s James Edwardes Jones in a report issued on April 29. However, on May 11, Barclays maintained a Buy rating on Haleon PLC (LSE: HLN).

AllianceBernstein

Barclays

Bernstein Reaffirms Their Hold Rating on Haleon PLC (HLN)

Jefferies analyst David Hayes has reaffirmed a Buy rating on Haleon PLC (HLN) with a price target of p400.00. Hayes, who specializes in the Consumer Defensive sector, has an average return of 2.9% and a 58.60% success rate on his stock recommendations. Additionally, Barclays analyst Warren Ackerman also issued a Buy rating for Haleon PLC, while Deutsche Bank maintained a Sell rating on the same day.

Jefferies Financial

Unilever PLC

Unilever

Nestlé S.A.

Nestlé

Deutsche Bank AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Jefferies Reaffirms Their Buy Rating on Haleon PLC (HLN)

In a report released today, Olivier Nicolai from Goldman Sachs maintained a Buy rating on Haleon PLC, with a price target of p450.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks According to TipRanks, Nicolai is ranked #4412 out of 12160 analysts. In a report released today, Barclays also maintained a Buy rating on the stock with a £4.15 price target.

iShares US Pharma

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

VG Health

Goldman Sachs

GS Hldg R

Haleon PLC (HLN) Gets a Buy from Goldman Sachs

Haleon rose 7.53% in the after-hours market; Eli Lilly rose 0.25% in the after-hours market, with a trading volume of USD 6.99 million; Novo Nordisk fell 0.77% in the after-hours market, with a trading volume of USD 954,800; Pfizer rose 0.11% in the after-hours market, with a trading volume of USD 805,900

Price Alert

Eli Lilly

Novo Nordisk AS

Pfizer

U.S. stock night trading fluctuations: Haleon rose 7.53% in after-hours trading, optimistic earnings guidance and executive appointments boost market confidence

Haleon has launched a soccer-themed marketing campaign featuring midfielder Tyler Adams ahead of the FIFA World Cup in the U.S. The campaign, titled "For the Assist," highlights Haleon's products like Advil and Sensodyne, showcasing how they support athletes. The ad includes a 30-second spot with Adams and will feature Crystal Dunn. Haleon is also selling limited-edition toiletry bags designed like soccer cleats. The company has strengthened its partnership with U.S. Soccer and recently appointed Richard Manso as U.S. chief marketing officer.

Haleon scores branding goal with star-studded soccer offensive

Haleon reported a decline in first-quarter sales due to a weak cold and flu season, with overall sales volumes down 0.2%. However, organic revenue grew by 2.2%, driven by a 10% increase in Sensodyne toothpaste sales. Analysts suggest that while Haleon has strong potential, it needs to improve performance across other product categories. The company, spun out from GSK in 2022, has a market value of approximately £31bn. Despite challenges, Haleon remains on track to meet its full-year guidance, with North America showing signs of growth.

cityam

Haleon takes hit from ‘weak cold and flu season’ but Sensodyne shines

Haleon reported a 2.2% rise in organic revenue for Q1, driven by its oral health segment, particularly Sensodyne and Parodontax, which saw 8.3% growth. Total revenue increased 0.1% to £2.86 billion. However, growth was impacted by a weak cold and flu season, with declines in respiratory and digestive health categories. North America saw a 1% organic revenue increase. The company anticipates full-year organic growth of 3% to 5%.

MorningStar

Sensodyne-Maker Haleon Revenue Rises on Oral Health Growth — Update

Haleon(HLN.US)